ZYNCET

For the use of a Registered Medical Practitioner or Hospital or a Laboratory only.

Abbreviated Prescribing information for ZYNCET TABLET (Cetirizine tablet)

[Please refer the complete prescribing information available at www.torrentpharma.com]

PHARMACOLOGICAL PROPERTIES: Cetirizine, a human metabolite of hydroxyzine, is a potent antihistamine, selective H1 receptor antagonist. In addition to its anti-H1 effect, cetirizine was shown to display anti-allergic activities: at a dose of 10 mg once or twice daily, it inhibits the late phase recruitment of eosinophils, in the skin and conjunctiva of atopic subjects submitted to allergen challenge.

DOSAGE AND ADMINISTRATION:

Children aged from 6 to 12 years: 5 mg twice daily (half tablet twice daily).

Adults and adolescents over 12 years of age: 10 mg once daily (1 tablet).

The tablets need to be swallowed with a glass of liquid.

CONTRAINDICATION: Hypersensitivity to the active substance, to any of the excipients, to hydroxyzine or to any piperazine derivatives. Cetirizine is also contraindicated in patients with severe renal impairment at less than 10 ml/min creatinine clearance.

WARNINGS & PRECAUTIONS: Urinary retention, epilepsy.

DRUG INTERACTION: No interactions are expected with this antihistamine. Actually, neither pharmacodynamic nor significant pharmacokinetic interaction was reported in drugdrug interactions studies performed, notably with pseudoephedrine or theophylline (400 mg/day). The extent of absorption of cetirizine is not reduced with food, although the rate of absorption is decreased. Precaution is recommended if alcohol is taken concomitantly.

ADVERSE REACTIONS: Thrombocytopenia, hypersensitivity, anaphylactic shock, increased appetite, agitation, aggression, confusion, depression, hallucination, insomnia, suicidal ideation, paraesthesia, convulsions, syncope, dysgeusia, tremor, dystonia, dyskinesia, amnesia, memory impairment, accommodation disorder, blurred vision, oculogyration, tachycardia, diarrhea, abnormal hepatic function, rash, pruritus, urticaria, angioneurotic oedema, fixed drug eruption, acute generalized exanthematous pustulosis (AGEP), arthralgia, dysuria, enuresis, urinary retention, asthenia, malaise, oedema.

MARKETED BY:

TORRENT PHARMACEUTICALS LTD.
Torrent House, Off Ashram Road,
Ahmedabad-380 009, INDIA
IN/ZYNCET/Apr-2020/01/ABPI
(Additional information is available on request)